LuMind IDSC Statement on FDA Approval of Leqembi
Last week the FDA announced a full approval of a new drug called Leqembi to…
Kim WarrenJuly 13, 2023
Adapting Eligibility Criteria for Prescribing FDA Approved Anti-amyloid Immunotherapeutics for Adults with Down Syndrome with Early-Stage Alzheimer’s Dementia
An international group of experts convened to determine prescribing criteria equivalences that would be inclusionary…